Negative Volume Index

(redirected from NVI)
Also found in: Acronyms, Wikipedia.

Negative Volume Index

In technical analysis, a measure of change in various market indicators on days when trading volume is low. The idea behind the NVI is that intelligent investors quietly buy or sell securities ahead of the trend, and that the crowd buys or sells only on days when trading volume is high. Tracking whether a market or security is bullish or bearish when trading volume is low is thought to be a lead indicator of a market's general direction. See also: Positive Volume Index.
Mentioned in ?
References in periodicals archive ?
14) Characteristics of neovascular glaucoma other than NVI include high IOP and trabecular meshwork blockage (16) (Figure 2).
Tyrimo metu is Vilniaus NVI paimtuose pudyto dumblo vandens eminiuose buvo gana didele amonio jonu koncentracija (iki 1750 mg/l).
NVI transferred its knowledge on vaccines mainly via the transfer of technology and stem cells to various public and private institutions.
As such, NVI is tasked with not only supplying high-quality vaccinations to the Dutch population, but also researching and developing better treatments and offering them at affordable prices.
NVI is a portfolio company of Berkshire Partners, which acquired the business in September, 2005.
Phil Smith, CEO of Cisco UK and Ireland, said: "We are delighted to partner with Sunderland and welcome the city to the NVI network.
March 30, 2012 /PRNewswire-USNewswire/ --The Department of Environmental Protection has received $33,000 from NVI LLC based in Gray, La.
Internap's flexible platform will allow NVI to meet its increasing IT Infrastructure demands, which are being driven by rapid growth.
BCIL); National Institutes of Health (NIH), USA; National Research Development Corporation of India; NVI Netherlands for inactivated polio vaccine; PT.
The Enhanced Charts exhibit a number of new features, including customizable parameters and new studies such as Chaikin, NVI, PVI, Stochastic RSI, TRIX and more.
NVI is the owner of proprietary polio (Salk IPV) strains and is a manufacturer of IPV vaccine, which it sells, and provides related technology transfer to various customers, particularly developing country manufacturers in Asia.